1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Northeast Pharmaceutical Group Co., Ltd.

Northeast Pharmaceutical Group Co., Ltd.

000597.SZ
Northeast Pharmaceutical Group Co., Ltd.CN flagShenzhen Stock Exchange
4.43
CNY
-0.07
- -
6.32BMarket Cap
Northeast Pharmaceutical Group Co., Ltd.
000597.SZ
(Shenzhen Stock Exchange)

Recent

price

4.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6.51
5.23
4.3
5.22
4.93
3.64
4.56
5.37
6.16
6.14
6.02
5.76
6.29
5.75
5.31
4.9
4.95
Revenue per Share
0.07
-0.53
0.01
-0.23
0.1
-0.36
0.02
0.11
0.16
0.13
0.01
0.07
0.25
0.25
0.29
0.18
0.26
Basic EPS, GAAP
-0.29
-0.88
-0.1
-0.97
-0.55
-0.23
0.2
-0.68
-0.23
0.09
0.14
0.44
0.62
0.25
0.42
0.7
-0.08
Free Cash Flow per Basic Share
0.22
0.19
0.2
0.26
0.23
0.17
0.15
0.15
0.14
0.1
0.1
0.12
0.08
0.15
0.15
0.14
0.15
Dividend per Share
1.52
0.98
0.82
0.77
0.91
0.39
0.41
0.52
0.68
0.98
1.44
1.3
1.6
1.7
1.91
1.94
1.85
Book Value per Share
1.64
1.16
1.02
1.09
2.23
1.48
1.48
1.51
2.23
2.22
2.57
2.34
2.75
3
2.84
2.84
2.77
Tangible Book Value per Share
742
742
900
741
879
1,053
1,056
1,057
1,212
1,338
1,226
1,415
1,401
1,434
1,413
1,445
1,453
Basic Weighted Avg Shares
4,828
3,883
3,865
3,871
4,333
3,834
4,814
5,676
7,467
8,220
7,384
8,145
8,809
8,243
7,503
7,075
7,187
Sales/Revenue/Turnover
3.69
-8.11
-4.15
-0.85
4.25
-5.13
4.06
6.44
6.32
5.45
4.41
4.37
5.15
7.84
8.84
7.05
8.71
Operating Margin (%)
190
218
159
148
171
213
317
326
323
340
481
551
561
575
572
542
- -
Depreciation Expense
53
-394
8
-167
87
-384
24
119
195
174
12
99
350
358
410
260
382
Net Income, GAAP
28.84
- -
87.22
- -
20.74
- -
29.61
9.9
5.79
23.99
88.21
20.57
32.03
22.98
28.73
28.64
22.76
Effective Tax Rate (%)
1.11
-10.15
0.21
-4.31
2.01
-10.02
0.49
2.1
2.61
2.12
0.17
1.22
3.98
4.35
5.46
3.68
5.32
Profit Margin (%)
1,000
-378
-763
-786
-275
-733
106
-469
-1,064
-2,020
-1,772
-1,399
-493
215
390
969
693
Working Capital
1,163
609
609
100
100
180
600
235
874
150
256
218
256
181
30
174
188
LT Debt
2,074
1,742
1,750
1,599
2,761
2,401
2,434
2,548
3,588
3,918
4,122
4,290
4,713
5,159
5,570
5,669
5,564
Total Equity
3.03
- -
-0.48
- -
2.84
- -
2.44
5.56
6.6
4.57
0.51
3.79
4.35
7.16
6.71
4.91
6.52
Return on Invested Capital (%)
3.74
- -
0.81
- -
5.65
- -
3.14
6.62
7.16
5.35
0.52
3.64
8.11
8.49
9.41
6.99
8.64
Return on Capital (%)
4.78
-42.58
1.11
-25.62
12.77
-63.65
5.62
24.04
28.38
16.34
0.8
5.49
17.15
15.31
15.95
9.46
14.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,598
2,026
1,754
LT Borrowings
- -
78
166
LT Finance Leases
30
27
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,429
1,429
1,427
Market Capitalization
7,593
7,337
7,497

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
8,646
7,941
8,171
Cash, Cash Equivalents & STI
4,468
3,386
3,829
Accounts Receivable, Net
1,959
2,395
2,324
Inventories
1,324
1,311
1,273
Total Current Liabilities
8,257
7,386
7,478
Payables & Accruals
- -
- -
- -
ST Debt
1,598
2,026
1,754
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.44%
6.63%
1.79%
Free Cash Flow
-41.09%
76.99%
68.29%
Net Income, GAAP
119.6%
188.35%
-36.54%
Sales/Revenue/Turnover
7.23%
-0.53%
-5.7%
Total Cash Common Dividend
5.36%
17.74%
-4.48%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,940
2,228
1,965
1,369
7,503
2025
1,947
1,905
1,597
- -
7,075
2026
2,006
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.29
2025
0.03
- -
- -
- -
0.18
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.15
2025
0.02
- -
- -
- -
0.14
2026
0.01
- -
- -
- -
- -
Similar Companies
Adastra Holdings Ltd. (XTRX.CN)
Lumiera Health Inc. (NHPHF)
Althea Group Holdings Limited (AGH.AX)
Cann Global Limited (CGB.AX)
MariMed Inc. (MRMD.CN)
SNDL Inc. (SNDL)
Business
Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) manufactures and sells chemical pharmaceuticals, including active pharmaceutical ingredients and formulations; engages in pharmaceutical commerce through wholesale and chain distribution; provides pharmaceutical engineering services such as design, manufacturing, and installation; and develops biomedicine products encompassing biological diagnostic reagents, cell therapy, and innovative biologics, primarily in China with exports to over 100 countries. The company produces ten major series of high-quality drugs, including vitamin series such as vitamin C, B1, and B6; anti-infection products like fosfomycin, azithromycin, and chloramphenicol; reproductive system and sex hormone products comprising carboprost and dapoxetine hydrochloride; nervous system drugs including piracetam; anti-AIDS medications such as zidovudine; digestive system products like sucralfate and berberine; cardiovascular and cerebrovascular medicines; analgesic and cough relief drugs; urinary system drugs; and big health field offerings, supported by over 400 chemical raw materials, intermediates, and formulations under trademarks "Northeast" and "Fumeixin". Founded in 1946 as Northeast Pharmaceutical General Factory and listed on the Shenzhen Stock Exchange in 1996, Northeast Pharmaceutical Group Co., Ltd. maintains headquarters in Shenyang, Liaoning Province, China, with production bases spanning 910,000 square meters for APIs and 180,000 square meters for formulations, and operates as a subsidiary of Liaoning Fangda Group Industrial Co., Ltd. In 2024, the company acquires 70% equity in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. for approximately CNY 187 million to enter solid tumor cell therapy, leveraging ADC, CAR-T, TCR-T, and TCR protein platforms for innovative biologics; deepens strategic cooperation with institutions like the Chinese Academy of Sciences; and advances cross-generational innovation in biological drugs while optimizing generic drug portfolios.